AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 793705
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only
Trial: 8515495
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with high-dose chemotherapy (cyclophosphamide 1875 mg/m2, cisplatin 55 mg/m2, carmustine 600 mg/m2) followed by autologous bone marrow reinfusion.
Trial: 8515495
Drug: Observation until
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation until relapse followed by the same high-dose chemotherapy and autologous bone marrow reinfusion.
Trial: 8515495
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (immediate treatment and observation)
Trial: 27579536
Drug: Tivantinib (MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (MET inhibitor)
Trial: 20698216
Drug: roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine acetate 75 mg twice daily (n = 16)
Trial: 20698216
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg once daily (n = 17)
Trial: 15880021
Drug: Everolimus dose
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus dose reduction
Trial: 15880021
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose furosemide
Trial: 6144462
Drug: Lorazepam 2.0
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2.0 mg
Trial: 20181388
Drug: Different preparation
RxNorm normalized name: Indifferent preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different preparation designs (non-retentive, occlusal preparation with chamfer or straight-beveled finishing line)
Trial: 19034051
Drug: Genistein (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein (54 mg/d)
Trial: 12087568
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered IV once weekly
Trial: 12087568
Drug: Epoetin administered
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin administered IV three times weekly
Trial: 8585775
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg trimethoprim and 800 mg sulfamethoxazole twice a day
Trial: 8585775
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ciprofloxacin twice a day
Trial: 1974143
Drug: Metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR (100 mg)
Trial: 1974143
Drug: Beta-adrenoceptor blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoceptor blockers (Propranolol LA, Atenolol, Metoprolol CR)
Trial: 875101
Drug: Massive steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massive steroids
Trial: 30361080
Drug: Imipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (25 mg once nightly for the first 2 weeks, then 50 mg thereafter)
Trial: 20124412
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of prednisolone (single dose)
Trial: 20124412
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of prednisolone daily for 15 days
Trial: 23676577
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg once daily
Trial: 10080158
Drug: IFN‐alpha (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha (6 million units once a day for one month and thrice weekly for five months)
Trial: 10080158
Drug: IFN‐beta (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐beta (6 million units once a day daily for two months)
Trial: 10080158
Drug: IFN‐beta (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐beta (3 million units twice a day for two months)
Trial: 22527350
Drug: Atropine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1.0 mg)
Trial: 1970284
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid enemas (4 gm daily for the first seven days of each month)
Trial: 1970284
Drug: Oral sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfasalazine (2 gm daily as oral tablets)
Trial: 6164465
Drug: Postoperative irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative irradiation (45 Gy) + Bleomycin (15 mg doses, total 180 mg)
Trial: 6164465
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care (no radiotherapy or chemotherapy)
Trial: 25897676
Drug: selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 75 mg p.o. bid
Trial: 25897676
Drug: selumetinib 50
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly
Trial: 21078303
Drug: Perimenopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perimenopausal hormone therapy (HT)
Trial: 21078303
Drug: Never users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Never users of hormone therapy (HT)
Trial: 17278974
Drug: Alagebrium (ALT-711;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alagebrium (ALT-711; 210 mg twice a day for 8 weeks)
Trial: 15126734
Drug: Amoxicillin/Clavulanate (A/C)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/Clavulanate (A/C)
Trial: 15126734
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Clarithromycin and A/C)
Trial: 10570555
Drug: Topical terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical terbinafine 1% cream twice daily for 1 week, followed by placebo cream for 5 weeks
Trial: 10570555
Drug: Topical clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clotrimazole 1% cream twice daily for 4 weeks
Trial: 320670
Drug: Topical clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clotrimazole
Trial: 6981176
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy for treatment: 20 mg of TMP and 100 mg of SMZ per kg of body weight per day
Trial: 6981176
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic therapy: 5.0 mg of TMP and 25 mg of SMZ per kg of body weight per day
Trial: 30507267
Drug: 12% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% carbohydrate plus electrolyte (CHO‐E) solution
Trial: 24296423
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri combination (2×10 Colony Forming Units)
Trial: 24296423
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri combination
Trial: 22676424
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg orally for 6 days)
Trial: 10627793
Drug: Paroxetine (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-50 mg/day flexible dose)
Trial: 6367380
Drug: Parenteral antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antihypertensive therapy
Trial: 22115710
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of sirolimus (220, 440, 880, 1320, or 1760 μg)
Trial: 22115710
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of sirolimus (44, 110, 176, 264, or 352 μg)
Trial: 21969992
Drug: Initial estimate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial estimate of the unknown factors of the G-computation formula
Trial: 15037403
Drug: GnRH‐a administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a administration starting on stimulation day 6 (group 1)
Trial: 15037403
Drug: GnRH‐a administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a administration starting when the leading follicle reached a mean diameter of 14 mm (group 2)
Trial: 11860914
Drug: Calcium lactate
RxNorm normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate tablets (800 mg of calcium daily)
Trial: 1432027
Drug: Sequential strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential strategy for determining antihypertensive intervention
Trial: 6499663
Drug: Oral instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral instructions alone or in combination with written information
Trial: 6499663
Drug: Medication reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reminder calendar
Trial: 6499663
Drug: Medication reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reminder package
Trial: 6499663
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reminder aid with oral reinforcement
Trial: 12529740
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus oral anticoagulants (group B)
Trial: 1090418
Drug: Indapamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (5 mg daily)
Trial: 1090418
Drug: Chlorothiazide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide (500 mg daily)
Trial: 25698298
Drug: WELLFOCUS PPT
RxNorm normalized name: PPT
DrugBank: Podofilox (DB01179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WELLFOCUS PPT + Treatment as Usual (TAU)
Trial: 24238308
Drug: Mesna injection
RxNorm normalized name: Mesna Injection
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna injection
Trial: 22852055
Drug: Natural orange
RxNorm normalized name: Dex4 Natural Orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural orange juice enriched with 11.25 g of levan
Trial: 14736583
Drug: e-diaries administered
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-diaries administered via home visits (n=30)
Trial: 10577813
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with ventilation tubes
Trial: 8597505
Drug: Chemotherapy (5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-Fluorouracil and cisplatin)
Trial: 1936647
Drug: Occlusin restorations
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusin restorations in butt-joint preparations
Trial: 1936647
Drug: Occlusin restorations
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusin restorations in bevel-edged preparations
Trial: 27500896
Drug: Serial glycolic
RxNorm normalized name: glycolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial glycolic acid (GA) peel every 3 weeks with twice daily 20% azelaic acid (AA) cream
Trial: 27500896
Drug: 20% azelaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% azelaic acid (AA) cream
Trial: 26763917
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg triflusal twice a day
Trial: 26763917
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel once daily
Trial: 24240777
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment aimed at lowering systolic blood pressure by 10% to 25% within the first 24 hours, achieving blood pressure less than 140/90 mm Hg within 7 days, and maintaining this level during hospitalization.
Trial: 24240777
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinued all antihypertensive medications during hospitalization).
Trial: 24240777
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment group.
Trial: 18562427
Drug: alprazolam 1
RxNorm normalized name: alprazolam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alprazolam 1 mg
Trial: 18562427
Drug: zolpidem 5
RxNorm normalized name: zolpidem 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zolpidem 5 mg
Trial: 17552957
Drug: Tolterodine extended-release
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine extended-release (ER)
Trial: 8424580
Drug: Intermittent suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent suction and pressure treatment
Trial: 3315536
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg once a day
Trial: 31751317
Drug: FMT capsules
RxNorm normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT capsules from a donor enriched in Lachnospiraceae and Ruminococcaceae
Trial: 27473187
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (600 IU daily or 3750 IU daily)
Trial: 24576844
Drug: Fish oil-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil-based parenteral lipid preparation (FOLP) at 1.5 g/kg/day
Trial: 24576844
Drug: Soy-based parenteral
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-based parenteral lipid preparation (SLP) at 1.5 g/kg/day
Trial: 24576844
Drug: Fish oil-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil-based parenteral lipid preparation (FOLP)
Trial: 15102335
Drug: Clonazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (1 mg)
Trial: 9568728
Drug: Sucralfate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (250 mg)
Trial: 8142151
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) alone (arm I: 26 patients)
Trial: 3060424
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg vaginal tablet once a month
Trial: 3060424
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg vaginal tablet once a month (after relapse)
Trial: 3060424
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg vaginal tablet twice a month
Trial: 1360087
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of Exosurf (synthetic surfactant)
Trial: 1360087
Drug: Delayed selective
RxNorm normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed selective administration of Exosurf (synthetic surfactant)
Trial: 1360087
Drug: Up-to-four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-to-four doses of surfactant (if signs of RDS persisted or recurred)
Trial: 1360087
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of surfactant 12 hours apart
Trial: 692138
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (chemotherapy, radiotherapy, immunotherapy)
Trial: 19220164
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation of azelastine nasal spray
Trial: 19220164
Drug: Original formulation
RxNorm normalized name: Zegerid (Original Formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original formulation of azelastine nasal spray
Trial: 25370394
Drug: Topical Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Anesthesia (TA)
Trial: 29444530
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no morphine)
Trial: 9152099
Drug: Continuous low
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low dose (2.5‐10 mg every 2 weeks)
Trial: 9152099
Drug: Continuous moderate
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous moderate dose (standard) (12.5‐50 mg every 2 weeks)
Trial: 8424849
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg SDZ ENA 713
Trial: 8424849
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg SDZ ENA 713
Trial: 8424849
Drug: 1.3 mg
RxNorm normalized name: menthol 1.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 mg SDZ ENA 713
Trial: 8424849
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg SDZ ENA 713
Trial: 3306291
Drug: Org OD
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD 14 (2.5 mg/day, per os)
Trial: 27339124
Drug: Morphine spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine spinal anesthesia
Trial: 25821098
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of proton pump inhibitor (PPI)
Trial: 25821098
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of proton pump inhibitor (PPI)
Trial: 23307404
Drug: CHO-PRO (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-PRO (0.8 g sucrose · kg‐1 · hr‐1 with 0.3 g · kg‐1 · hr‐1 whey-protein isolate)
Trial: 23307404
Drug: CHO (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (0.8 g sucrose · kg‐1 · hr‐1)
Trial: 23307404
Drug: CHO-CHO (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-CHO (1.1 g sucrose · kg‐1 · hr‐1)
Trial: 20805294
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98)
Trial: 18077611
Drug: Refrigerated formulation
RxNorm normalized name: Refrigerant 114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refrigerated formulation of Zostavax (n = 182)
Trial: 18077611
Drug: Frozen formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen formulation of Zostavax (n = 185)
Trial: 3839446
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin
Trial: 2249379
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg codeine
Trial: 6108299
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of oxazepam
Trial: 6108299
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of temazepam
Trial: 26996542
Drug: Control (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (insulin pump therapy)
Trial: 24614112
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (500 mg, three times a day)
Trial: 24614112
Drug: Cellulose (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose (placebo, 500 mg, three times a day)
Trial: 17903568
Drug: Hydrocodone with
RxNorm normalized name: Rolatuss with Hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone with acetaminophen
Trial: 2147833
Drug: Enoximone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (1 mg/kg by rapid intravenous injection every 8 hours for 48 hours)
Trial: 2147833
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (furosemide, nitrates, dopamine‐dobutamine)